Clinical Trials Logo

Filter by:
NCT ID: NCT05782270 Recruiting - Anticoagulation Clinical Trials

Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy

Start date: April 11, 2023
Phase: Phase 4
Study type: Interventional

Coronary endarterectomy (CE) combined with coronary artery bypass grafting (CABG) can be the final option for achieving complete revascularization in diffuse coronary artery disease patients. Since the exposure of subendothelial tissue to the blood flow after CE, the coagulation cascade can be activated, resulting in the increased risk of graft failure. Therefore, anticoagulation with warfarin in this group of patients might be beneficial. However, evidence is limited. This study aims to compare the clinical outcomes between dual antiplatelet therapy with or without warfarin after CE+CABG.

NCT ID: NCT05782205 Recruiting - Mental Health Clinical Trials

Surgeons' Mental Distress and Risks After Severe Complications Following Radical Gastrectomy

Start date: June 1, 2023
Phase:
Study type: Observational

Surgeons experience higher levels of work stress, even under normal circumstances. Many can suffer from substantial levels of mental health issues, especially when faced with severe complications. However, due to a variety of reasons, many surgeons are reluctant to disclose mental health issues or seek psychological help. Gastric cancer is the fifth most common malignancy globally and accounts for the fourth leading cause of death from cancer. In China specifically, gastric cancer is a major public health issue, with some 400,000 new cases diagnosed every year. Of those cases, more than 80% patients are at advanced stages when diagnosed. At present, radical gastrectomy is considered the standard approach for patients with resectable advanced gastric cancer. Severe complications following radical gastrectomy ranged from 2.7% to 9.4% worldwide. In addition to delaying patients' recovery courses, severe complications also place enormous pressure on chief surgeons who performed the operations. Such pressures may bring great risks of psychological distress. Surgeons are also the victims when they encounter severe complications following radical gastrectomy. Their mental distress should not be minimized. Until now, little has been known about the effects of surgical complications on surgeons. In the current study, based on a large-scale questionnaire survey in China, the investigators aimed to investigate incidences of surgeons' mental distress following severe complications after radical gastrectomy. The investigators also aimed to identify independent risk factors which could help develop strategies to improve the mental well-being of these surgeons after such incidences.

NCT ID: NCT05782036 Recruiting - Clinical trials for Postoperative Recovery

Dynamic Characterization of Postoperative Recovery After Cardiac Surgery

Start date: April 1, 2023
Phase:
Study type: Observational

With the improvement of surgical techniques and medical care levels, most cardiac surgery patients have a good prognosis, and the long-term postoperative survival rate of some surgical patients has not significantly differed from that of the general population. While cardiac surgery is traumatic for patients and has a long postoperative recovery cycle, the recovery of patients is equally of concern. Postoperative recovery is a complex concept involving multiple domains, including patients' physiological functions, mental health, and pain, etc. These states will not only continuously change over time, but also the situation of postoperative recovery in patients with different characteristics is very different. Accordingly, the investigators aim to characterize trajectories of patient recovery after cardiac surgery using PROMs. The investigators will conduct a prospective study to characterize trajectories of postoperative recovery in multiple domains after cardiac surgery.

NCT ID: NCT05781880 Recruiting - Clinical trials for Acute Ischemic Stroke

Normobaric Hyperoxia Stabilizing Ischemic Penumbra

Start date: March 22, 2023
Phase: N/A
Study type: Interventional

To investigate the safety and efficacy of normobaric hyperoxia (NBO) stabilizing penumbra in acute ischemic stroke patients.

NCT ID: NCT05781750 Recruiting - Lupus Nephritis Clinical Trials

A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)

Start date: November 3, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of zetomipzomib (30 mg or 60 mg) compared with placebo in achieving renal response after 52 weeks of treatment in patients with active lupus nephritis (LN).

NCT ID: NCT05781659 Recruiting - Pleural Effusion Clinical Trials

The Effectiveness and Safety of Ultrasound Elastography Guided Pleural Biopsy in the Differential Diagnosis of Benign and Malignant Pleural Effusion

Start date: April 7, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the diagnostic effcacy and safety of ultrasound elastography guided pleural biopsy in the differential diagnosis of benign and malignant pleural effusion. The main question it aims to answer are: the effectiveness and safety of ultrasound elastography guided pleural biopsy in the differential diagnosis of benign and malignant pleural effusion. Participants will undergo ultrasound elastography guided pleural biopsy or traditional ultrasound-guided pleural biopsy.

NCT ID: NCT05781633 Recruiting - Clinical trials for Mammary Neoplasms, Human

The Efficacy and Safety of Eutideron, Etoposide, and Bevacizumab in Patients With Brain Metastases From Breast Cancer.

Start date: July 20, 2022
Phase: N/A
Study type: Interventional

This study was a single-arm, open-label, phase II study of breast cancer patients with brain metastases. Eligible patients received a regimen of eutidrone(30mg/m2/d,iv,d1-5,21d/cycle), etoposide(30mg/m2/d,iv,d1-3,21d/cycle), and bevacizumab (10mg/kg,d1,21d/cycle).At least 4 to 6 cycles were administered, and if patients had a response or stable disease, bevacizumab was used as maintenance therapy until disease progression or intolerable toxicity.

NCT ID: NCT05781607 Recruiting - Clinical trials for Temporomandibular Joint Disorders

Long-term Efficacy of Physical Therapy for TMDs

Start date: April 7, 2023
Phase:
Study type: Observational

Physical therapy is one of the initial conservative treatments for TMD. Many studies and previous studies in our department have proved that it can improve the pain, mouth opening and mandibular function of patients with TMD. However, the current research on physical therapy for TMD has a short follow-up period, which cannot prove that the patients' long-term mandibular function has improved, and few studies have analyzed the relevant factors affecting the curative effect. Therefore, this study is intended to adopt a retrospective cohort study to include TMD patients who received physical therapy in our department from 2016.01-2021.12. The patients' pain, joint area noise, mandibular range of motion, mandibular function and other conditions will be followed up by remote telephone or online questionnaire, and the patients' demography, clinical symptoms, pain, oral habits, depression, anxiety, sleep status, head and neck posture and other information will be collected. The multiple regression analysis model will be used to compare and analyze the relevant factors affecting the prognosis of patients, and to intervene in advance the factors that have a significant impact on the prognosis of the disease, so as to improve the treatment effect.

NCT ID: NCT05781594 Recruiting - Clinical trials for Family Genetic Characteristics of Osteoporosis

Family Cohort Study on Primary Osteoporosis

Start date: October 1, 2022
Phase:
Study type: Observational [Patient Registry]

Bone metabolism and genetic characteristics of osteoporosis pedigree with kidney-yang deficiency

NCT ID: NCT05781516 Recruiting - Clinical trials for IgG4-related Disease With Eosinophilia

Baricitinib Plus Glucocorticoid for Eosinophilia in IgG4-RD

Start date: January 20, 2023
Phase: N/A
Study type: Interventional

Evaluation of efficacy and safety of Baricitinib combined with glucocorticoid in patients of IgG4-related disease with eosinophilia.